Company intelligence / Profile preview

VisCardia

Beaverton, Oregon, United Statesviscardia.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Preclinical and First-in-Human trials have demonstrated safety of the implant procedure and proprietary SDS/ADS therapy. Early feasibility studies showed improvements in acute hemodynamic parameters and chronic left ventricular ejection fraction without adverse effects. The company has received FDA IDE approval for a pivotal randomized controlled trial ("RECOVER HF") to further evaluate efficacy. In May 2025, the company was honored with a major innovation award at EuroPCR for its disruptive approach to heart failure management.

Therapeutic areas: Cardiovascular
Modalities: DeviceImplantable device therapy
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

VisONE System

Phase 2

Indications: Heart failure with reduced ejection fraction

Partnerships

Clinical collaboration with University Hospital of ZurichClinical collaboration with Robertson Centre for Biostatistics at University of GlasgowKinetic Capital Partners (investor/partner)MedTech Innovator (investor/partner)

Beyond the preview

Go deeper on VisCardia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VisCardia.

Explore the full profile